La fluorocholine(18F) a une utilité clinique dans le cancer de la prostate et le carcinome hépatocellulaire… parfois chez le même malade |
| |
| Authors: | S Balogova F Bumsel K Kerrou V Huchet V Nataf F Mal F Gutman F Montravers J-N Talbot |
| |
| Institution: | 1. Department of Neurology, Kyungpook National University Hospital, Daegu, South Korea;2. Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea;3. Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea;4. Department of Neurology, Dongsan Medical Center, Keimyung University, Daegu, South Korea;5. Department of Neurology, Bobath Memorial Hospital, Seongnam, South Korea;6. Department of Neurology, Best Heals Hospital, Ansan, South Korea;7. Department of Neurology, Metro Hospital, Anyang, South Korea;8. Department of Neurology, The Good Light Hospital, Gwangju, South Korea |
| |
| Abstract: | Case reportIn order to stage hepatocellular carcinoma (HCC), a patient was referred to PET/CT using fluorodeoxyglucose(18F) (FDG) and, if necessary, fluorocholine(18F) (FCH). HCC was proven by biopsy of a hepatic mass discovered on CT performed for a biological recurrence of prostate cancer.ResultFDG PET/CT did not show any anomaly. FCH PET/CT was thus performed and showed various foci: the hepatic mass, a large abdominal adenopathy and an unexpected subcentimetre lung nodule. The diagnostic uncertainty mostly concerned this lung nodule which was biopsied and consisted of a metastasis of the prostate cancer. Due to the presence of two metastatic cancers, the patient's management was altered, with chemotherapy for the HCC and hormone therapy for the prostate cancer.ConclusionSeveral types of cancer take-up fluorocholine(18F), which is a powerful tool to detect metastases, in particular in case of rising levels of marker with a negative FDG PET/CT. Even when FDG PET/CT is positive, FCH may reveal unexpected foci with other metabolic characteristics, although it is not specific of a given primary cancer, as well as FDG. For staging of HCC, we thus recommend to perform PET/CT with both tracers. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
